On June 28, medical big data technology and artificial intelligence solution provider Yidu Technology Co., Ltd. ("Yedu Technology" or "Company", together with its subsidiaries and integrated affiliated entities, collectively referred to as the "Group", stock code 2158. HK ) Announced the audited consolidated annual results (hereinafter referred to as the "Report") for the fiscal year ending March 31, 2021 (the "2021 fiscal year" or "period").
First of all, combing out the results for the 2021 fiscal year, revenue increased by 55.4% year-on-year to RMB 867 million, of which: the big data platform and solutions sector increased by 8.1% year-on-year to RMB 402 million; the life science solutions sector increased by 79.3% year-on-year to RMB 1.84 100 million yuan; the health management platform and solutions segment increased by 353.1% year-on-year to 252 million yuan.
Gross profit increased by 123.4% year-on-year to RMB 327 million; gross profit margin increased by 11.5 percentage points year-on-year to 37.8%.
Non-IFRS adjusted net loss narrowed by 14.7% year-on-year to RMB 275 million.
As of March 31, 2021, the company's data infrastructure has covered more than 500 medical institutions and companies in more than 20 provinces across the country, and has established a specialized disease database in more than 50 disease fields, enabling efficient and rapid production of research-level evidence. Out.
Nearly a hundred papers have been produced based on Yidu Technology's specialized disease database and big data platform.
According to the report, in the 2021 fiscal year, Yidu Technology continues to consolidate the medical big data infrastructure YiduCore, and at the same time vigorously expand the new business established on YiduCore through existing customers and new customers. The total revenue reached 867 million yuan, a year-on-year increase of 55.4%; gross profit margin 37.8%, an increase of 11.5 percentage points year-on-year.
As of March 31, 2021, Yidu Technology's business has covered more than 500 medical institutions in more than 20 provinces across the country, and the quality and efficiency of data processing have been steadily improved.
In addition, Yidu Technology cooperates with well-known hospitals and experts to enable the company to continuously establish and enrich disease labeling systems in various disease fields, and to further improve and refine the real world through the use of symbolic knowledge reasoning models and artificial intelligence technologies such as deep learning Disease model.
The report pointed out that Yidu Technology has established a specialized disease database in more than 50 disease fields, enabling the efficient and rapid output of research-level evidence. The specialized disease database and big data platform based on Yidu Technology have produced nearly 100 articles. paper.
As of the end of this fiscal year, Yidu Technology has applied for 905 patents (including 522 invention patents), of which 428 have been authorized and approved (including 59 invention patents), and its independent research and development technology strength has continued to strengthen.
The report also shows that in the big data platform and solution sector, revenue during the period reached 402 million yuan, an increase of 8.1% year-on-year, and the gross profit margin was 45.1%, an increase of 11.7% year-on-year.
As of March 31, 2021, Yidu Technology has provided solution services for 76 Chinese research hospitals, 19 government agencies and regulatory agencies.
At the same time, the life science solutions segment achieved revenue of RMB 184 million during the reporting period, an increase of 79.3% year-on-year, and its gross profit margin was 21.7%, an increase of 8.3 percentage points year-on-year.
The number of customers in this sector has grown rapidly. The number of active customers throughout the year increased by 45.9% year-on-year to 108, and there were 25 new active customers from core pharmaceutical, biotechnology and medical device companies.
Yidu Technology provides life science solution services to 15 of the top 20 international pharmaceutical companies in the world in terms of revenue in 2020.
In addition, while expanding the number of customers, Yidu Technology is also actively expanding the types and numbers of solutions provided to individual customers to enhance customer value and stickiness.
During the period, the revenue retention rate for customers purchasing life science solutions was 124%, of which the revenue retention rate for customers from core pharmaceutical, biotechnology and medical device companies reached 141%.
The revenue of the health management platform and solutions segment was 252 million yuan, a significant year-on-year increase of 353.1%, and the gross profit margin was 40.7%.
Utilizing the medical knowledge and AI empowerment accumulated on YiduCore, Yidu Technology has built a "factor health" brand under this sector, providing an integrated health management solution based on evidence-based medicine, and providing insurance with the "factor cloud" brand Companies and insurance brokerage companies provide insurance technology and disease management solutions.
As of the end of the reporting period, more than 5 million paying users had made at least one purchase on the health management platform of Yidu Technology.